$94M Stock Offering at 7% Discount to Fund Key Drug Trial
ANRO has more than doubled off its 52-week low of $2.5 on elevated volume (4.6× avg).
Summary
Alto Neuroscience is selling 3.78M shares at $26.48, a 7% discount to the last close, raising $93.9M net. The offering is led by BofA Securities with Stifel, William Blair, and Baird as joint bookrunners. Proceeds are earmarked for an additional Phase 3 trial of ALTO-207, the company's lead asset, and general working capital. The discount and dilution are material for a ~$984M market cap biotech, but the raise funds a clear catalyst. The stock is near its 52-week high, so the discount may pressure shares short-term. Closing is expected today, July 14, 2026.
At the time of this announcement, ANRO was trading at $28.50 on NYSE in the Life Sciences sector, with a market capitalization of approximately $983.7M. The 52-week trading range was $2.50 to $28.44. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.